Transcode Therapeutics Inc. (RNAZ) stock soars during pre-market trading session, given no recent update.

Transcode Therapeutics Inc. (NASDAQ: RNAZ) stock surged by 21.93% at last close while the RNAZ stock-price gains by 20.16% in the pre-market trading session. However, Transcode therapeutics has not released any news regarding the share price. TransCode is an up-and-coming RNA oncology business founded on the premise that cancer may be vanquished via the intelligent design and delivery of RNA therapies. Transcode Therapeutics has developed a portfolio of therapeutic candidates that target a range of tumor types with the goal of improving patient outcomes considerably.

>> 7 Top Picks for the Post-Pandemic Economy << 

TTX-MC138, RNAZ’s primary therapeutic candidate, is aimed at curing metastatic cancer, which accounts for over 90% of all cancer deaths globally, or over nine million fatalities each year.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Recent Development

TransCode Therapeutics has priced its first public offering of 6,250,000 shares of its common stock at $4.00 per share, for gross revenues of $25,000,000 before underwriting discounts and offering expenses. Transcode Therapeutics has also given the underwriters a 45-day option to acquire up to an extra 937,500 shares of common stock at the initial public offering price, minus the underwriting discount, to meet over-allotments. Transcode Therapeutics is offering all of the shares of common stock.

Read More


Transcode Therapeutics plans to use the funds for the testing necessary to submit an IND for the Phase 0 trial of TTX-MC138, as well as for continued development of TTX-MC138, strategic growth of their drug candidate portfolio, and operating capital.On July 9, 2021, the shares will begin trading on the Nasdaq Capital Market under the ticker “RNAZ.” The offering is scheduled to close on July 13, 2021, assuming all usual closing conditions are met.

The offering’s only book-running manager is ThinkEquity, a part of Fordham Financial Management.

Most Popular

Related posts